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Abstract
Better understanding of the distinct and redundant functions of the proprotein convertase (PC) enzyme family within
pathophysiological states has a great importance for potential therapeutic strategies. In this study, we investigated
the functional redundancy of PCs in prostate cancer in the commonly used androgen-sensitive LNCaP and the
androgen-independent DU145 human cell lines. Using a lentiviral-based shRNA delivery system, we examined in vitro
and in vivo cell proliferation characteristics of knockdown cell lines for the endogenous PCs furin, PACE4, and PC7 in
both cell lines. Of the three PCs, only PACE4 was essential to maintain a high-proliferative status, as determined
in vitro using XTT proliferation assays and in vivo using tumor xenografts in nude mice. Furin knockdowns in both cell
lines had no effects on cell proliferation or tumor xenograft growth. Paradoxically, PC7 knockdowns reduced in vitro
cellular proliferation but had no effect in vivo. Because PCs act within secretion pathways, we showed that condi-
tioned media derived from PACE4 knockdown cells had very poor cell growth–stimulating effects in vitro. Immuno-
histochemistry of PACE4 knockdown tumors revealed reduced Ki67 and higher p27KIP levels (proliferation and cell
cycle arrest markers, respectively). Interestingly, we determined that the epidermal growth factor receptor signaling
pathway was activated in PC7 knockdown tumors only, providing some explanations of the paradoxical effects of PC7
silencing in prostate cancer cell lines. We conclude that PACE4 has a distinct role in maintaining proliferation and
tumor progression in prostate cancer and this positions PACE4 as a relevant therapeutic target for this disease.
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Introduction
The mammalian proprotein convertases (PCs) form a family of enzymes
that is responsible for the activation of numerous protein precursors
within the secretory pathway. Nine different PCs have been identified,
namely, furin, PACE4, PC1/3, PC2, PC4, PC5/6, PC7, PCSK9, and
SKI-1/S1P [1,2]. Only the first seven of these serine proteases pro-
cess substrates with an optimal PC recognition sequence R-X-K/R-R↓,
whereas the minimal consensus sequence is R-X-X-R↓. A variety of
substrates have been described such as precursors of hormones, enzymes,
growth factors, receptors, cell membrane proteins, and plasma proteins
but also a number of pathogenic proteins such as viral glycoproteins
and bacterial toxins. There is growing evidence for the involvement of
PCs in various cancer types, including roles in each of the biologic
capabilities acquired during the multistep development of human tu-
mors [3]. These biologic capabilities include proliferative signaling [4],
evading growth suppressors [5], enabling replicative immortality [6],
inducing angiogenesis [7], and activating invasion and metastasis [8].
Abbreviations: PC, proprotein convertase; RPMI, Roswell Park Memorial Institute
medium; FBS, fetal bovine serum; EGF(R), epidermal growth factor (receptor); PSA,
prostate-specific antigen; MVD, microvessel density; NT, non-target
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Prostate cancer is a worldwide health problem and is the second
leading cause of cancer deaths behind lung cancer in North American
men [9]. Prostate cancer threatens the life of patients by its ability to
overcome initial hormone therapies as it becomes castration resistant,
which then limits traditional therapeutic interventions and leads to
metastasis and poor prognosis. Thus, the identification and valida-
tion of novel pharmacological targets suitable for the treatment of
such aggressive tumors represents an unmet need.
In a recent study, we showed that PACE4 was highly overexpressed in
prostate cancer tissues [10]. PACE4 silencing, based on an engineered
delta-ribozyme approach, in the androgen-independent DU145 prostate
cancer model cell line resulted in reduced proliferation and tumor xeno-
graft progression in athymic nude mice. We thus hypothesized that
PACE4 may be a potential druggable target for prostate cancer. If this
is the case, then further information on the role of co-expressed PCs in
prostate cancer becomes essential as redundancy among the PCs is well
established. Thus, in prostate cancer, we raise the question as to whether
the sole inhibition of PACE4 would suffice to produce beneficial ef-
fects or whether other PCs should also be considered for inhibition
to attain this goal. Therefore, in the present study, we examined the
role of other PCs in the cellular proliferation and tumor progression
of prostate cancer cells using molecular silencing methods. We used
lentivirus-delivered shRNAs to knockdown furin, PC7, and PACE4
in the androgen-sensitive LNCaP cell line and also in the androgen-
independent DU145 cell line and then examined cell proliferation and
tumor growth characteristics, in vitro and in vivo.
Materials and Methods
Cell Culture
All cell lines used were obtained from ATCC (Manassas, VA).
Human prostate cancer cell lines DU145 and LNCaP were maintained
in Roswell Park Memorial Institute medium (RPMI 1640) supple-
mented with either 5% fetal bovine serum (FBS; Wisent Bioproducts,
St Bruno, Canada) for DU145 or 10% for LNCaP. Human embryonic
kidney 293FT cells (HEK293FT; Invitrogen, Carlsbad, CA) were grown
in Dulbecco’s modified Eagle’s medium and 10% FBS supplemented
with 6 mM glutamine and 500 μg/ml G418. HT1080 cells were grown
in Dulbecco’s modified Eagle’s medium with 10% FBS. Cells were
grown at 37°C in a water-saturated atmosphere with 5% CO2.
Lentivirus Production and shRNA Transduction
Production of lentiviral particles containing the MISSION RNAi
pLKO.1-puro vector (see Table W1 for shRNA sequences) was car-
ried out in HEK293FT cells following manufacturer’s instructions
(Sigma-Aldrich, St Louis, MO). Viral titers were calculated using a
serial dilution approach with HT1080 cells. Lentivirus transductions
were carried out in 6-well plates with 6 × 104 cells or in 12-well
plates with 5 × 104 cells (for DU145 and LNCaP, respectively) with
a multiplicity of infection of 3. After 2 days, the infected cells were
selected using growth medium containing 1 or 2 μg/ml puromycin,
respectively, for LNCaP and DU145 cells. Cells were further cul-
tured under selective pressure using media with these puromycin
concentrations for culture on passages. On characterization, the
selected polyclonal cell populations were used for further studies
to avoid any artifact associated with individual clone selection
[11]. Cell populations were cultured for 10 to 12 passages before
being discarded.
Real-time Quantitative Polymerase Chain Reaction
Total RNA was extracted using the Qiagen RNA Isolation Kit
(Qiagen, Valentia, CA). RNA quality was assessed using an Agilent
Bioanalyzer with RNA Nano Chips (Agilent Technologies, Palo
Alto, CA). For tumor RNA isolation, Trizol-chloroform extractions
(Invitrogen) were carried out on tissues crushed in liquid nitrogen.
Real-time quantitative polymerase chain reaction (qPCR) reactions
were performed as previously described [10]. Briefly, 1 μg of RNA
was reverse transcribed and qPCR analysis reactions were done with
a Stratagene Mx3005P instrument. All primers used are listed in
Table W2. Relative expression levels were calculated using β-actin as a
reference gene with the formula (1 + amplification efficiency)−Δ(ΔCT).
Experiments were done in duplicate in three independent experiments
(n = 3).
XTT Proliferation Assay
The cellular proliferation was measured with the colorimetric XTT
Cell Proliferation Kit II following the manufacturer’s instructions
(Roche Applied Science, Indianapolis, IN). Briefly, cells were seeded
(1000 cells/well for DU145 and 3000 cells/well for LNCaP) in four
96-well plates in triplicate. For the next days, a plate was revealed
after a 4-hour incubation with the reagent solution. Absorbance
values were measured at a wavelength of 490 nm with a reference
at 690 nm in a microplate reader (SpectraMax190; Molecular De-
vices, Sunnyvale, CA). For each time point, data were reported as
percentage of mean values measured at 24 hours with corrections
applied for the respective blanks (complete medium).
Conditioned Growth Medium Preparation and
Proliferation Induction Measurements
As previously described, conditioned media were produced from
four 10-cm plates seeded with 1.0 × 106 cells in complete growth media
[10]. The next day, the cells were washed twice with phosphate-
buffered saline (PBS) and the growth media were replaced with 5 ml
of serum-free RPMI for 1 hour. The conditioned media were then
collected, filtered through 0.45-μm filters, and concentrated to a
final volume of 350 μl with Amicon Ultra centrifugal filter devices
(Millipore, Billerica, MA) with a 3-kDa molecular weight cutoff. Fresh
RPMI medium was treated the same way as a control.
The potential of these concentrated media to induce proliferation
was measured as follows: for DU145, 50 μl of conditioned media was
applied on control or shRNA-transfected cells seeded in 96-well
plates (2000 cells/well) in triplicate. After a 48-hour incubation
period, 12.5 μl of Thiazolyl Blue Tetrazolium Blue (MTT) compound
(5 mg/ml; Sigma-Aldrich) was added to each well (25 μl for LNCaP).
After a 4-hour incubation, the medium was carefully removed and
cells were solubilized with a mixture of isopropanol/1N HCl (25:1).
For LNCaP cells, 4500 cells/well were used and 50 μl of conditioned
media was added to 50 μl of fresh 5% FBS medium.
The absorbance was measured at a wavelength of 550 nm with
a reference at 650 nm in a microplate reader. MTT was used instead
of XTT because the latter would have required a specific background
subtraction for each conditioned medium generated.
Western Blot Analysis
Total proteins were extracted from excised tumors crushed in
liquid nitrogen using RIPA buffer supplemented with protease in-
hibitors (complete Mini; Roche). Protein concentrations were deter-
mined using a BCA Protein Assay Kit (Pierce, Rockford, IL) and
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50 μg of protein samples were separated on a sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to a nitrocellulose
membrane (Hybond; GE Healthcare, Chalfont St Giles, United
Kingdom). Before immunodetection, membranes were blocked with
5% (wt/vol) BSA in a 0.1% Tween-PBS solution. Membranes were
then incubated with anti-actin (NeoMarkers, Fremont, CA), anti–
epidermal growth factor receptor (EGFR; Signalway Antibody,
SAB, Pearland, MD), anti–phospho-Ser1070–EGFR (SAB) primary
antibody overnight at 4°C followed by incubation with a goat anti-
rabbit or anti-mouse IgGs coupled to IRDye800 (LI-COR Bio-
sciences, Lincoln, NE). Immunodetection was then performed using
an infrared imager (Odyssey Imager, LI-COR Biosciences). Relative
protein expression levels were calculated using the ImageJ software.
Human Tumor Xenograft Models
Four- to six-week-old male athymic nude mice (Nu/Nu; Charles
River Laboratories, Lasalle, Canada) were inoculated subcutaneously
on the opposite sides of the flanks and shoulders with 2.0 and 3.0 ×
106 cells per inoculum, respectively, for LNCaP and DU145 (five
mice per group). Cells were grown in complete media and harvested
at their exponential growing state. Mice were housed under pathogen-
free conditions and the inoculations were done under isoflurane
anesthesia conditions in a laminar flow hood. For LNCaP cells only,
100 μl of cell suspension in cold PBS was mixed with 100 μl of
matrigel before injection (BD Biosciences, Bedford, MA). Xenografts
were measured three times per week and volumes (V ) were deter-
mined using the formula V = (L × W 2) × π/6, where L is the tumor
length and W is the tumor width. For prostate-specific antigen (PSA)
monitoring, blood samples were collected weekly in heparinized
micro-hematocrit capillary tubes (Thermo Fisher Scientific, Waltham,
MA) from mice saphenous vein. Blood samples were kept on ice with
10 U of heparin until a 10-minute centrifugation at 3500g was per-
formed to collect plasma. Plasmatic and cell growth medium PSA
concentrations were determined using a PSA ELISA Test Kit (ClinPro
International, Union City, CA).
Immunohistochemistry
On mice sacrifice, tumors were eradicated, formalin fixed, and
paraffin embedded. Immunohistochemistry (IHC) was performed on
5-μm sections in the Department of Pathology, Centre Hospitalier
Universitaire de Sherbrooke (CHUS; Sherbrooke, Canada) using the
standard streptavidin-biotin-peroxidase immunostaining procedure with
a VentanaNexES autostainer and the solvent-resistantDABMapDetec-
tion Kit (Ventana Medical System, Tucson, AZ). Antibodies (p27KIP,
1:100 and EGFR, 1:800) and ready-to-use solutions (p53, PSA, Ki67,
CD34) were purchased from Dako Canada (Burlington, Canada).
For Ki67 proliferation index determination, up to five representative
fields containing an average of 150 cells were captured for each analyzed
tumor and were used to manually count cells with positive nuclear
staining that were reported on the total number of cells per field. For
immunostaining quantifications, the yellow channel of a CMYK color
model for each picture taken on a SuperCoolscan 9000 (Nikon, Tokyo,
Japan) was extracted using Fiji software (Open Source) and used to
quantify staining density relative to tumor area [12]. To avoid quan-
tification of any off-tumor area (e.g., skin and fat), we counterstained
tumor areas using hematoxylin and eosin (H&E) additionally to p53
or PSA as a positive marker for DU145 and LNCaP cells, respectively.
Pictures with ×100 and ×400 magnification were acquired using an
Axioskop 2 phase-contrast microscope (Carl Zeiss, Thornwood, NY)
and processed using Image Pro software (Media Cybernetics, Bethesda,
MD). Microvessel densities (MVDs) were calculated by counting the
number of microvessels positive for CD34 immunostaining divided by
their respective tumor area. The tumor areas were determined using
the ImageJ software with ×15 magnified images.
Statistical Analysis
All experiments were repeated at least three times, and the results
were expressed as mean ± SEM. Statistical analysis was done using
Student’s t test to calculate P values.
Results
Knockdown of Endogenous PCs in Prostate Cancer Model
Cell Lines
In a previous study, we characterized PCs only in the DU145 cell
line, showing PACE4, furin, and PC7 mRNA expression [10]. Herein,
we first characterized PC expression in DU145 and LNCaP prostate
cancer cell lines and demonstrated a similar PC expression pattern,
with the exception that LNCaP expressed three-fold higher levels of
PACE4 than the DU145 (Figure 1A). This characterization of PC
expression levels in LNCaP and DU145 cells was carried out to define
the PC targets for the subsequent molecular silencing studies. There-
fore, we decided to develop knockdown LNCaP and DU145 cell lines
for furin, PACE4, and PC7. Considering the number of cell lines
required, we chose an RNA interference approach using lentiviral-
based delivery system. Viral particles coding for shRNAs specific to
each PC were prepared from five MISSION shRNA vectors available
from Sigma-Aldrich. The best shRNA for each PC target (i.e., furin,
PACE4, and PC7) was selected on the basis of their silencing efficiency
(Figure W1 and Table W2).
Stable knockdown polyclonal cell lines were obtained through
puromycin selection, whereas the non-target (NT) shRNA and the
empty PLKO vectors were both used as controls (Figure 1, B and
C ). The resulting puromycin-resistant cell populations were assessed
for their expression level of each endogenous PC by real-time qPCR
on total RNA. When compared to the NT control cells, significant
knockdowns were obtained for all cell lines, with less than 25% re-
sidual expression remaining and without major compensatory over-
expression of any other PC. In the DU145 cells, knockdown levels
for furin, PACE4, and PC7 were, respectively, 93%, 78%, and 87%
of control cells expression levels. For the LNCaP cell lines, PC knock-
down levels were, respectively, 92%, 85%, and 93% when compared
to controls. As empty vector–infected cell lines were exempt of any
significant variation in PC expression levels, the silencing method
was considered valid and reliable. We validated the stability of the
mRNA knockdowns for up to 30 passages (data not shown).
Effect of PC Knockdowns on Cell Proliferation
To determine the effects of endogenous PC knockdowns on the
growth capabilities of LNCaP and DU145 cell lines, we measured
their proliferation rates using the XTT assay on a 96-hour time course.
This colorimetric assay allows the direct measurement of cellular
proliferation rates by monitoring the metabolic reduction of the re-
agent in a soluble formazan. As shown in Figure 2A, DU145 cell lines
silenced for PACE4 or PC7 showed significantly reduced proliferation
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rates after 72 and 96 hours with overall reductions of, respectively,
50% and 68% relative to NT control cells. No significant difference
was observed for the DU145 furin knockdown cell line. Similar results
were obtained with the LNCaP cell lines, as significant differences
could be observed after 48 hours (Figure 2B). Reductions in prolifera-
tion rates were of about 45% and 30% for the LNCaP PACE4 and
PC7 knockdowns, respectively, with no significant difference for the
LNCaP furin knockdowns.
Secreted Growth Factors Are Implicated in PC-mediated
Proliferation Effects
As PCs act in secretory pathways, we evaluated the growth induc-
tion potential of conditioned media derived from the knockdown
cells of both DU145 and LNCaP. We hypothesized that any pro-
liferation rate reductions in PC knockdown cells could be due to re-
duced self-sustaining growth factor activity. The reduction of growth
factor activity would be the result of reduced processing by the PC
knockdown. Serum-free conditioned media were produced under
short incubation conditions to prevent cell quiescence and possible
secretome degradation and to avoid the application of exogenous
growth factors. After concentration, the conditioned media were ap-
plied on their respective NT control cells to test cell proliferation
induction. Figure 3, A and B, presents the results of these medium
swap experiments using DU145 and LNCaP NT control cell lines.
Concentrated RPMI growth medium was applied on cells as a meth-
odology control. We observed that the conditioned media derived
from PACE4 and PC7 knockdown cell lines led to significant growth
reduction of both DU145 (39% and 35%, respectively) and LNCaP
(35% and 30%, respectively). However, no significant difference
was observed with the conditioned media obtained from the furin
knockdown DU145 cell line. These data suggest that PACE4 and
PC7 are more important in the activation of secreted growth factors
than furin. To ascertain this hypothesis, we also tested the effect of
conditioned media obtained from control DU145 cell lines (NT)
and applied them to the PACE4- (Figure 3C) and PC7 (Figure 3D)–
silenced DU145 cell lines. In both cases, this control conditioned
medium rescued PACE4 and PC7 knockdown cell growth by 70%
when compared to conditioned medium derived from the tested cell
line (74% for PACE4 and 73% for PC7).
Only PACE4 Down-regulation Prevents Prostate Tumor
Growth In Vivo and Reduces Neovascularization
We then tested the ability of furin-, PACE4-, and PC7-silenced
DU145 and LNCaP cell lines to form tumor xenografts in immuno-
deficient mice after subcutaneous inoculations. Tumor growth was
first monitored by periodically measuring their volume (Figure 4,
A and B). As we previously reported, PACE4 silencing in DU145 cells
led to a significant reduction in tumor growth where tumor volume
was 60% smaller than controls (Figure 4A). However, no significant
difference was observed for the furin and PC7 knockdown DU145
cell lines, even 33 days post-implantation (Figure 4A). These ob-
servations were identical for xenografts derived from LNCaP knock-
down cell lines, where the phenotype was even more pronounced
for the PACE4-silenced cells, as these cells were unable to form tumors
bigger than 15% to 20% of the control tumor volumes (Figure 4B).
Endpoint analyses were performed by excising and weighing tumors
(Figure 4C ). Tumors from LNCaP PACE4–silenced cells weighed
10 ± 2 mg, whereas tumors from control cells weighed 90 ± 20 mg
(Figure 4C ). No significant difference was observed for tumors derived
from furin and PC7 knockdown LNCaP cells.
Because LNCaP cells secrete PSA, we verified whether tumor xeno-
graft volumes correlated with plasmatic PSA concentrations [13].
Plasma samples from xenografted mice were collected on a weekly
basis. As control, we first verified if the secretion of PSA from all
knockdown lines was affected. As no significant variation in PSA
Figure 1. Stable knockdown of endogenous PCs in DU145 and
LNCaP prostate cancer cells. (A) Real-time qPCR measuring rela-
tive endogenous PC mRNA expression levels in DU145 and LNCaP
wild-type cells. PC knockdown assessment by real-time qPCR on
DU145 (B) and LNCaP (C) shRNA–expressing cell lines. The mRNA
expression levels of other endogenously co-expressed PCs (furin,
PACE4, and PC7) were also determined. Data are means ± SEM
(n = 3) of mRNA levels relative to NT using β-actin as reference
gene. *P < .05.
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Figure 2. Cellular proliferation on PC knockdown. (A) DU145 cells (1 × 103 cells/well) or (B) LNCaP cells (3 × 103 cells/well) were plated in
96-well plates with, respectively, 5% and 10% FBS. Every 24 hours, XTT was added to each well and incubated 4 hours to monitor growth
rates for each cell line. Values are means ± SEM (n = 3) of the increases of XTT signal (OD490 nm–OD690 nm) relative to the 24-hour reading
for each cell line. *P < .05.
Figure 3. Mitogenic properties of secreted factors derived from PC knockdown cell lines. (A) DU145 and (B) LNCaP NT control cells
(1.5 × 103 and 4.5 × 103 cells/well, respectively) were plated in 96-well plates with complete media. After 24 hours, media were replaced
by either serum-free (uncond. med.), concentrated serum-free (conc. uncond. med.), or conditioned media derived from knockdown cell
lines. X-axis labels correspond to the cell lines that produced the conditioned medium applied. After 48 hours, MTT reagent was added to
each well, and following an incubation period of 4 hours, absorbance values (OD550 nm–OD650 nm) of cell lysates were read using a spec-
trophotometer. DU145 shPACE4 (C) and shPC7 (D) cell lines were plated and used to compare growth rates on conditioned medium
application. Values are means ± SEM (n = 3) of the absorbance for each condition relative to serum-free medium-treated cells. *P < .05.
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secretion was observed, we considered that PSA monitoring in vivo
would correlate with tumor progression (Figure 4D). Figure 4E shows
that PSA levels measured in the tumor-carrying mice ranged from 15
to 40 ng/ml for all mice except those with PACE4-silenced LNCaP
xenografts, where background levels of 3 ng/ml were consistently
measured. Our observations provide supporting data that these cells
were unable to form tumors during the 40+-day experiments, as some
tumors completely disappeared before the end of the experiment.
LNCaP cells normally form xenografts with a distinct dark red color,
which is associated with extensive neovascularization [14,15]. How-
ever, PACE4-silenced LNCaP tumors lacked this characteristic darker
color, as shown in Figure 5A. This reddish coloration is most probably
due to erythrocytes within the tumor as visible on the H&E in Fig-
ure W2. The color of xenografts derived from furin and PC7 knock-
downs were similar to the controls. MVDs shown in Figure 5B were
calculated using CD34 immunostaining (Figure 5, C and D), a marker
of endothelial cells in tumors [16]. The 80% reduction inMVDbetween
NT and shPACE4 supported the notion that tumors derived from
PACE4-silenced cells were less vascularized than the control tumors.
The Silencing of PACE4 in Prostate Cancer Cell Lines
Enhances Quiescence in Tumor Xenografts
At the end of each xenograft formation assay, the tumors were
excised and paraffin embedded for further IHC analyses using cell
proliferation markers. As shown in Figure 6, A and B, Ki67 immuno-
staining, a strict marker of cellular proliferation, revealed a statistically
reduced number of cells undergoing cell cycle progression in the
tumors issued from PACE4-silenced cells (50% and 90% reduction
in Ki67 proliferation index compared to controls, for DU145 and
LNCaP cell lines, respectively). The DU145 tumors silenced for furin
and PC7 had a very slight, but significant, reduction of their prolifer-
ation index (around 15%). No significant difference was observed for
the furin and PC7 knockdown LNCaP xenografts.
We also tested p27KIP immunostaining, a cyclin-dependent kinase
(CDK) inhibitory protein implicated in the blocking of the cell cycle
transition from the G0/G1 to S phase transition during cell quiescence
and subsequently degraded on mitogenic signaling [17]. Higher
immunolabeling of p27KIP was observed only in xenografts resulting
from PACE4-silenced cells. Tumors derived from PACE4-silenced
Figure 4. In vivo tumorigenicity assay of PC knockdown prostate cancer cell lines. (A) 3.0 × 106 DU145 cells and (B) 2.0 × 106 LNCaP
cells were subcutaneously injected on both flanks and hips of four-week-old nu/nu male mice (four injections per mice; five mice per
group). The length and the width of the tumors were measured periodically. Values shown are means ± SEM of tumor volumes for all
tumors measured per mice group [volume = (width)2 × length × π/6]. (C) LNCaP tumor weight on excision from mice at the end of the
experiment showing the remarkably smaller tumors generated by PACE4 knockdown cells. (D) Measurements of the PSA levels in the
concentrated normalized conditioned medium from LNCaP cell lines (Figure 3) normalized on protein content determined by a BCA
protein assay. (E) Plasmatic PSA concentrations from blood samples taken on a weekly basis during the xenograft experiment with
LNCaP-derived cell lines. *P < .05, **P < .01, ***P < .001.
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DU145 cells had more than two-fold increase in p27KIP whereas the
PACE4-silenced LNCaP cells showed a four-fold increase (Figure 6,
C and D), while no significant changes were observed in other PC-
silenced cell lines.
We also tested the EGF signaling pathway, as a previous report
showed a link between this signaling pathway and PC7 [18] and also
because EGFR has been reported to enhance prostate cancer cell growth
and invasiveness [19,20]. EGFR immunostaining remained relatively
unchanged in xenografts derived from PACE4 or furin knockdown
DU145 or LNCaP cells. However, EGFR levels were much higher in
xenografts issued from PC7-silenced DU145 and LNCaP cells, with
respective increases of 75% and 150% in comparison to control tumors
(Figure 6, E and F). To determine whether these higher levels of EGFR
were contributing to the restored proliferative capabilities of PC7 knock-
down xenografts, we immunoblotted both EGFR and phosphorylated
EGFR on DU145 xenograft protein extracts. Figure 7A confirms
that not only EGFR but also phosphorylated EGFR (PS1070-EGFR;
phosphorylation on Ser1070) protein levels were truly increased in PC7
knockdown tumors, whereas in PACE4 and furin knockdown xeno-
grafts, levels remained statistically unchanged for both proteins. These
results are in agreement with immunostaining results (Figure 6E). We
also tested furin, PACE4, and PC7 mRNA levels in the tumor xeno-
grafts (Figure 7B) and the changes observed correlated with the Western
blot (Figure 7A) and immunostaining analyses even if statistical sig-
nificance was not reached (Figure 6E). Thus, EGFR protein and activa-
tion levels increase only in xenografts derived from PC7 knockdown
cell lines. However, when we went back to verify EGFR and phosphory-
lated EGFR proteins in the original cell lines, no changes were observed
for both EGFR and phosphorylated EGFR levels in the PC7 knock-
down cell lines or in any other PC knockdown cell lines (Figure 7C).
These results support the observed disparity between in vitro and in vivo
growth conditions having an impact on cell behavior.
Discussion
The PCs are thought to play important roles in cancer development
and progression. While they are essential for normal cells, cancer cells
also appear to heavily depend on their processing activities for main-
tained survival and progression. However, it is unclear if PCs are
constitutive players or have distinct functions in specific steps of cancer
progression. Distinct and redundant PC functions remain an impor-
tant issue, not only at the individual substrate processing level but also
in more global cellular processes. Therefore, in the context of provid-
ing evidence for PCs as druggable targets in cancer, answers to these
questions are essential. Our previous work suggested that PACE4 plays
a major role in prostate cancer, but, until now, we were unable to
compare functional aspects with other expressed PCs. We now provide
evidence that PACE4 has a distinct role on prostate cancer cell prolif-
eration that is not sustained by furin or PC7 redundant functions.
Attempts to define prostate cancer regulatory networks have been
made and lead to complex signaling networks interconnected at various
points of convergence [21]. The data highlight the critical roles of auto-
crine and paracrine growth factors in tumor progression. Such cellular
modulators are part of the epithelial and stromal interactions, which
are crucial in the complex mechanisms leading to tumor progression
and metastasis [22–24]. Growth factors are especially important actors
in prostate carcinoma, as they are known to substitute androgens by
multiple alternative mechanisms leading to preserved proliferative re-
sponse [25–27]. As with the tumor microenvironment, the extracellular
matrix is also extensively remodeled in terms of integrin and matrix
metalloproteinase composition during prostate carcinogenesis and is
associated with tumor invasiveness and metastatic dissemination of
cancer cells, which is the major cause of cancer-associated mortality
[28,29]. Many of these tumor progression–related proteins are known
to be concurrently overexpressed in prostatic neoplasms [30–32]. How-
ever, the multiple efforts made to develop targeted therapeutic agents
were mostly unsuccessful [33]. As we now understand more about can-
cer progression from the point of view of a system’s biology approach,
we have come to realize that many of these tumor microenvironment
actors share common mechanisms of biologic activation, being synthe-
sized as inactive proproteins. Indeed, most growth factors [e.g., EGF,
transforming growth factor β, insulin-like growth factor I/II (IGF-I/II)],
growth factor receptors (e.g., IGF1R and Notch1), some integrins, and
matrix metalloproteinases require at least one activating proteolytic
cleavage achieved by the PCs [34].
In spite of this understanding, PCs have not been widely appreciated
as drug targets in cancer because of several factors. First, PC enzymes
Figure 5. Xenograft MVD of tumors derived from LNCaP cell lines.
(A) Representative LNCaP tumors showing the distinctive white color
of tumors derived from PACE4 knockdown cells. (B) MVD calculated
for the NT and shPACE4 tumors using CD34 immunostaining. CD34
staining of NT (C) and (D) shPACE4 LNCaP tumors. Arrows point
to microvessel lumens. Scale represents 25 μm. *P < .05.
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are widely expressed in tissues and it has been speculated that their
systemic inhibition would be a drawback, causing important secondary
effects. Second, it has been anticipated that beneficial effects might be
limited because of known redundant functions among the PCs. As
a counterpoint to both arguments, PCs can be considered as useful
pharmacological targets if redundancy serves to preserve the overall
functions of normal cells, whereas target cells, such as cancer cells, may
be more dependent on a single PC for survival and may thus be vul-
nerable to the inhibition of that PC [2]. This idea is compatible if that
PC sits at a strategic hub that regulates the activities of multiple cancer-
promoting proteins. It is therefore possible to imagine that a single com-
pound targeting a single PC for inhibition, for example, PACE4, could
have a major impact on cancer progression. This could occur through
the simultaneous inhibition of a large number of growth factors, by
blockade of the processing activation step, as a general way of reducing
many associated downstream signaling pathways. Indeed, growth factor
signaling pathways have been proposed as key therapeutic targets in
prostate cancer [26,35,36], but their simultaneous inhibition has been
problematic considering their high number.
In this study, we tested whether PACE4 is a unique target in prostate
cancer progression and whether future anticancer compounds should
be designed to also target other PCs. Molecular silencing techniques
are the most effective way to obtain such proofs of concept. We used
a lentivirus shRNA delivery approach that most appropriately per-
mitted us to rapidly produce cell lines with significantly silenced PC
mRNA expression levels (typically 80–90% reductions). PACE4-
silenced DU145 cells using this lentivirus approach behaved just like
the switch on/off adapter (SOFA)-hepatitis delta virus ribozyme
(HDVRz)-mediated PACE4-silenced DU145 cells in our previous
report [10], solidifying our contention of the vital role of PACE4 in
Figure 6. IHC against cell cycle markers and EGFR protein for DU145 and LNCaP tumor xenografts. (A and B) Ki67, (C and D) p27KIP, and
(E and F) EGFR IHC quantifications relative to respective NT control in both DU145- and LNCaP-derived tumors. Ki67 proliferation index
was determined by counting cells with positive nuclear staining in the representative field. p27KIP and EGFR immunostaining densities
relative to tumor areas, which were confirmed by counterstaining (H&E and positive marker; p53 for DU145 and PSA for LNCaP, respec-
tively), were quantified using CMYK quantification. Pictures are representative fields of DU145 staining for each tumor type [original
magnification, ×400 (Ki67) and ×100 (others)]. Scale bar represents 25 μm (Ki67) and 100 μm (others). *P < .05, ***P < .001.
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prostate cancer cell survival. The use of two completely different meth-
odologies resulting in identical data nullifies potential arguments that
observed antiproliferative effects are due to major cell aberrations or tox-
icity due to technical manipulations. Additionally, similar antiprolifera-
tion effects were observed when PACE4 was silenced in LNCaP cells.
In an attempt to determine how PACE4 silencing works in pros-
tate cancer cells, we carried out medium swap experiments, providing
proof of the attenuated secretion of active mitogenic growth factors
(Figure 3). The lack of mitogenic activity was associated with higher
cell quiescence states characterized by the increase of p27KIP, as ob-
served in the resulting tumor xenografts (Figure 6). p27KIP is a CDK
inhibitor protein that binds and prevents the activation of cyclin
E–CDK2 or cyclin D–CDK4 complexes and thus controls the cell
cycle progression at the G1 phase. PACE4 silencing in DU145 and
LNCaP cells was also associated with a considerable decrease in Ki67-
positive cells in tumor xenografts. Ki67 is a nuclear protein associ-
ated with ribosomal RNA transcription and is a cellular marker that
is strictly associated with cell proliferation. Though the sum of these
data leads us to conclude that PACE4 has a critical role in prostate
cancer cell proliferation. Additionally, we propose that PACE4 is a
hub protein for the proliferative response in prostate neoplasia [37].
The concept of hub proteins has been put forth for protein interactors
and deletion of such protein has direct consequences often resulting
in lethality. In some systems, these hub proteins are considered as
“master switches” controlling the regulation of entire pathways. It
should be noted that we propose PACE4 as a hub protein only in
the pathophysiological processes of prostate cancer cells and not in
normal cells. The principal reason we do not include normal cells is
related to the results obtained with PACE4 knockout mice. PACE4
knockout mice are viable, although it was initially reported that lethality
occurred in 25% of mutant homozygous offspring, while others ex-
hibit craniofacial abnormalities [38]. However, the penetrance of this
phenotype appears to be rather low, as the deletion of PACE4 results in
normal mice without any lethality when performed in the C57BL/6
instead of the SV129 background [39]. As prostate cancer cells are
known for their extreme genetic heterogeneity [40,41], it remains a
challenge to define hub proteins in tumor maintenance processes that
could serve as effective targets. Downstream pathways that are insured
by hubs that are involved in proteolytic activation could be suitable for
targeted therapies, with the aim to treat primarily cancer cells without
affecting normal tissues [42].
In regard to the other two PCs highly expressed in prostate cancer
cells, namely, furin and PC7, it was important to verify if they also had
important roles to play in tumor progression. In previous studies,
furin was described as having an important association with cancer/
tumorigenesis processes as it cleaves many cancer-associated protein
precursors [34]. Surprisingly, in prostate cancer cells, we did not ob-
serve any effects following furin silencing, as the cells were entirely
viable and formed xenografts with identical characteristics to control
cells. Previous studies have reported that a full furin knockout is
lethal to mice [43], which has led to the still accepted suggestion
that inhibition of furin in any cell would lead to cell death. However,
other studies have shown that the lethality of furin inhibition during
early phases of embryonic development can be overcome under phys-
iological conditions, as demonstrated by conditional furin knockouts
[44,45]. This suggests that cells can survive without furin, most likely
as other PCs are providing sufficient compensatory functions. In re-
gard to cancer cells, the situation remains confused, as, for example,
it has been recently reported that furin overexpression in hepatocellular
carcinoma cells was associated with growth reduction [46,47]. More-
over, high furin levels in clinical hepatocellular carcinoma specimens
were correlated with a better postoperative disease–free survival. The
apparent paradoxical results lead us to state that general conclusions
about a single PC are not applicable to all cancer types. A PC may
fulfill a specific role in one cancer cell type but not in another. Addi-
tionally, predictions solely based on genetic models or cultured cells
may also not be realistic.
In regard to PC7, we observed paradoxical effects between the in vitro
and in vivo phenotypes of the PC7-silenced DU145 and LNCaP cells.
For both cell lines, in vitro proliferation rates were reduced, whereas
in vivo xenograft growth was unaffected and comparable to control
cells (Figures 2 and 4). In an attempt to understand these observations,
we tested various cellular markers using IHC and molecular analysis
of both cell lines and derived tumors (Figures 6 and 7). Xenografts
from PC7-silenced LNCaP and DU145 cells displayed highly increased
Figure 7. EGFR Western blots on DU145-derived tumors. (A and B)
Tumor lysates were analyzed for their EGFR and phospho-Ser1070-
EGFR contents by Western blots and for their EGFR mRNA expres-
sion levels by real-time qPCR. Two tumors per knockdown/control
were assayed using β-actin as a loading control for Western blots
and as the reference gene for qPCR. (C) Cell lysates were also as-
sessed for their protein levels by Western blots. *P< .05, **P< .01.
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levels of EGFR, as well as EGFR phosphorylated on Ser1070 (i.e., its
activated form). This was not observed when these same cell lines
were under cell culture conditions. Combined with the restoration of
their Ki67 proliferation index in these xenografts, we conclude that
PC7 inhibition improves pro-proliferative cell capabilities in vivo.
Indeed, EGFR has been described as an important driver of DU145 cell
proliferation and invasiveness both in vitro and in vivo [19,20,48]. In
LNCaP cells, it is well known that mitogenic steroid concentrations
induce cell proliferation by mediating an increase in EGFR protein,
making them more sensitive to surrounding ligands [49,50]. Thus,
PC7 may be implicated in growth inhibitory mechanisms, which are
only discernible in vivo.
From the present study, we conclude that PACE4 carries out a dis-
tinct function in prostate cancer cells, critical for cell proliferation,
tumor progression, and vascularization, as these functions were not
duplicated by furin or PC7. It was conceivable, and even likely, that
cleavage sites in cancer-associated proteins processed by PACE4 could
be redundantly processed by furin and PC7. However, blockade of
furin and PC7 did not translate into the blockade of a global function
such as in vivo tumor progression, whereas that of PACE4 does. From
a therapeutic point of view, we conclude that drugs targeting PACE4
should be highly effective in prostate cancer and do not need to
encompass the additional inhibition of other PCs. PACE4 is a critical
driver in the prostatic neoplastic process and strengthens its position
as a novel pharmacological target in prostate cancer.
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Table W1. Specific shRNA Silencing Sequences.
Number* Target Gene Sequence TRC Number†















shRNAs in bold are the ones selected for this study because of their higher efficiency.
*shRNA numbers used for Figure W1.
†TRC number from Sigma–Aldrich for human genes.
Table W2. qPCR Primer Sequences.
Gene Protein Primer Sequences Product Size (bp)
ACTB β-Actin Forward: 5′-CAGAGCCTCGCCTTTGCCGATC-3′ 280
Reverse: 5′-CGATGCCGTGCTCGATGGGG-3′
PCSK3 Furin Forward: 5′-GTGGCGACCTGGCCATCCAC-3′ 251
Reverse: 5′-AGGTACGGGCAGCCCCTCAG-3′
PCSK6 PACE4 Forward: 5′-CACCTGCTAGTGAAGACATCC-3′ 122
Reverse: 5′-AACGAGAGCTTCTGCGTCCAC-3′
PCSK7 PC7 Forward: 5′-GGGTCACCAACGAGGCAGGC-3′ 391
Reverse: 5′-CCCCCAGCATCGCACAGTGG-3′
EGFR EGFR Forward: 5′-CCTGGTCTGGAAGTACGCAG-3′ 126
Reverse: 5′-GCGATGGACGGGATCTTAGG-3′
Figure W1. shRNA efficiency screening on DU145 cells. Northern blot hybridization densitometry of furin, PACE4, and PC7 mRNA relative
to 18S RNA on total mRNA extracted from DU145 transfectants for the five shRNAs targeting furin (top), PACE4 (middle), and PC7 (bottom).
Radioactive probes used are the same as in [10] (for shRNA numbers, refer to Table W1).
Figure W2. H&E staining on LNCaP tumors. H&E staining confirms
the high vascularization of LNCaP tumor (NT on this picture), as
multiple erythrocytes can be observed (red cells lacking purple
nucleus) among the tumor cells within the tumors. Scale bar repre-
sents 100 μm.
